Chempro Pharma Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 08-07-2024
- Paid Up Capital ₹ 0.01 Cr
as on 08-07-2024
- Company Age 16 years 4 months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
as on 08-07-2024
- Satisfied Charges ₹ 3.00 Cr
as on 08-07-2024
- Revenue -4.73%
FY 2022
- Profit -32.01%
FY 2022
- Ebitda -26.30%
FY 2022
- Net Worth 5.54%
FY 2022
- Total Assets -20.75%
FY 2022
About Chempro Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.01 Cr.
The Corporate currently has active open charges totaling ₹2.00 Cr. It has already closed loans amounting to ₹3.00 Cr, as per the Ministry of Corporate Affairs (MCA) records.
Arun Sehgal, Vijay Agarwal, Vandan Agarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH2008PTC182363
- Company No.
182363
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Chempro Pharma Private Limited offer?
Chempro Pharma Private Limited offers a wide range of products and services, including Ferro Alloys, High Carbon Ferrochrome, Ferro Vanadium, Ferro Molybdenum, Ferro Manganese, Silico Manganese, High Carbon Ferro Manganese.
Who are the key members and board of directors at Chempro Pharma?
Board Members(4)
Financial Performance and Corporate Structure Insights of Chempro Pharma.
Chempro Pharma Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 4.73% decrease. The company also saw a substantial fall in profitability, with a 32.01% decrease in profit. The company's net worth moved up by a moderate rise of 5.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chempro Pharma?
Unlock access to Chempro Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Mahavir Laboratories Private Limited
Active
16 years 4 months Arun Sehgal and Vijay Agarwal are mutual person
Goldstar Chemicals Private Limited
Active 36 years 11 months Arun Sehgal and Vijay Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Mar 2017 | ₹2.00 Cr | Open |
Deutsche Bank Ag Creation Date: 02 Sep 2013 | ₹3.00 Cr | Satisfied |
How Many Employees Work at Chempro Pharma?
Unlock and access historical data on people associated with Chempro Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Jan 05, 2015, Chempro Pharma has raised a total of ₹ 3.65 M, with the most recent deal valued at ₹ 3.65 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
